ArticleTheranostics2013
CXCR4 chemokine receptor overview: biology, pathology and applications in imaging and therapy.
Article in Theranostics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Advances in GPCR-Targeted PET Radiotracer Patents (2020-2025).Pharmaceuticals (Basel, Switzerland) · 2026Review
- Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- FKBP5 isoforms shape immune pathways related to tumor tolerance.Cell death discovery · 2026Article
- The Role of 68Ga-Pentixafor and 18F-Fluorodeoxyglucose (18F-FDG) PET/CT in a Case of Multiple Myeloma.Cureus · 2026Article
- Exploring pUS27: Insights into Its Role in HCMV Pathogenesis and Potential for Antiviral Strategies.Pathogens (Basel, Switzerland) · 2025Review
- Synthesis andChemMedChem · 2025Article
- Article
- On the automated radiosynthesis of pharmaceutical grade [Scientific reports · 2025Article
- The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?Frontiers in pharmacology · 2024Review
- CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors.Molecules (Basel, Switzerland) · 2023Review
- Novel characterization of CXCR4 expressing cells in uninfected and herpes simplex virus-1 infected corneas.The ocular surface · 2023Article
- Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma.Phenomics (Cham, Switzerland) · 2022Review
- Article
- Reduced splenic uptake onTheranostics · 2022Article
- Regulation of Tumor and Metastasis Initiation by Chemokine Receptors.Journal of Cancer · 2022Review
- CXCR4 protects bone marrow-derived endothelial progenitor cells against hypoxia through the PI3K/Akt signaling pathway.Experimental and therapeutic medicine · 2021Article
- Review
- CXCR4 PET imaging of mantle cell lymphoma using [Theranostics · 2021Article
- Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.Diagnostics (Basel, Switzerland) · 2020Review
- CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.